(Q33425338)

English

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 September 2017

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study (English)

1 reference

Europe PubMed Central

30 September 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

myelodysplastic syndrome

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

19

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

30 September 2017

Jean-Pierre J Issa

object named as

Jean-Pierre J Issa

1

0 references

4

object named as

Elias Jabbour

1 reference

Europe PubMed Central

30 September 2017

3

object named as

David Rizzieri

1 reference

Europe PubMed Central

30 September 2017

11

object named as

Naval Daver

1 reference

Europe PubMed Central

30 September 2017

2

object named as

Gail Roboz

1 reference

Europe PubMed Central

30 September 2017

Casey J McConnell

6

object named as

Casey O'Connell

1 reference

Europe PubMed Central

30 September 2017

8

object named as

Raoul Tibes

1 reference

Europe PubMed Central

30 September 2017

Katherine G Walsh

10

object named as

Katherine Walsh

1 reference

Europe PubMed Central

30 September 2017

5

object named as

Wendy Stock

1 reference

Europe PubMed Central

30 September 2017

Mohammad A Azab

18

object named as

Mohammad Azab

1 reference

Europe PubMed Central

30 September 2017

12

object named as

Woonbok Chung

1 reference

Europe PubMed Central

30 September 2017

17

object named as

James N Lowder

1 reference

Europe PubMed Central

30 September 2017

author name string

Karen Yee

7

1 reference

Europe PubMed Central

30 September 2017

Elizabeth A Griffiths

9

1 reference

Europe PubMed Central

30 September 2017

Sue Naim

13

1 reference

Europe PubMed Central

30 September 2017

Pietro Taverna

14

1 reference

Europe PubMed Central

30 September 2017

Aram Oganesian

15

1 reference

Europe PubMed Central

30 September 2017

Yong Hao

16

1 reference

Europe PubMed Central

30 September 2017

publication date

18 August 2015

1 reference

Europe PubMed Central

30 September 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

30 September 2017

16

1 reference

Europe PubMed Central

30 September 2017

9

1 reference

Europe PubMed Central

30 September 2017

1099-1110

1 reference

Europe PubMed Central

30 September 2017

Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557041

21 June 2018

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557041

21 June 2018

S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557041

21 June 2018

Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557041

21 June 2018

Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557041

21 June 2018

Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557041

21 June 2018

A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557041

21 June 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557041

21 June 2018

Worms gang up on bacteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557041

21 June 2018

In vitro cytotoxic and biochemical effects of 5-aza-2'-deoxycytidine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557041

21 June 2018

Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557041

31 October 2018

Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5557041

31 October 2018

The fundamental role of epigenetic events in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900038-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting DNA methylation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900038-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900038-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900038-8

7 January 2021

based on heuristic

inferred from DOI database lookup

2010 white paper on recent issues in regulated bioanalysis & global harmonization of bioanalytical guidance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900038-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900038-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)00038-8

1 reference

Europe PubMed Central

30 September 2017

1 reference

Europe PubMed Central

30 September 2017

1 reference

Europe PubMed Central

30 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33425338&oldid=1975277162"